<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496882</url>
  </required_header>
  <id_info>
    <org_study_id>201911095MIPD</org_study_id>
    <nct_id>NCT04496882</nct_id>
  </id_info>
  <brief_title>Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue</brief_title>
  <acronym>CHANGE</acronym>
  <official_title>The Clinical Efficacy of Tenofovir Alafenamide-switching Therapy in Patients With Chronic Hepatitis B Experiencing Clinical Flare-up After Discontinuation of Nucleos[t]Ide Analogues Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital, Yun-Lin Branch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiayi Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalin Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a phase 4, multicenter, open-label trial at 7 academic centers in Taiwan.&#xD;
&#xD;
      Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir&#xD;
      disoproxil fumarate [TDF]) for at least 2 years, and fulfil the following nucleos(t)ide&#xD;
      analogs discontinuation criteria. After nucleos(t)ide analogs discontinuation, patients had a&#xD;
      clinical relapse and retreatment regimen switches to TAF.&#xD;
&#xD;
      The protocol will be approved by Institutional Review Board (IRB) or Research ethic committee&#xD;
      (REC) of each site and will be conducted in accordance with the principles of Declaration of&#xD;
      Helsinki and the International Conference on Harmonization for Good Clinical Practice. Each&#xD;
      patient provides written informed consent before enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tenofovir alafenamide (TAF) is a new generation of oral antiviral drugs with similar&#xD;
      antiviral activities to tenofovir disoproxil fumarate (TDF) and reduces the adverse effects&#xD;
      of nephrotoxicity and bone mineral density reduction. This drug has already been reimbursed&#xD;
      by National Health Insurance, and can be used for the treatment of patients with chronic&#xD;
      hepatitis B.&#xD;
&#xD;
      This is a single-arm prospective clinical trial to enroll patients who discontinued entecavir&#xD;
      (ETV) and tenofovir disoproxil fumarate (TDF) and experienced a clinical hepatitis flare up.&#xD;
      They can be retreated with TAF for 48 weeks without postponing a 3-month observation period&#xD;
      for alanine aminotransferase (ALT) level. The virological control, ALT level recovery, and&#xD;
      changes in liver fibrosis, hepatitis B surface antigen, hepatitis B core-associated antigen,&#xD;
      and renal function will be observed during retreatment. In addition, a group of patients with&#xD;
      the same characteristics who received retreatment with entecavir or TDF will be collected as&#xD;
      a control group for comparison. We believe this study can help us understand the clinical&#xD;
      benefits of switching to TAF for retreatment after hepatitis flare in patients to discontinue&#xD;
      oral antiviral agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of virological remission (HBV DNA &lt;20 IU/mL)</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will calculate the rate of virological remission (HBV DNA &lt;20 IU/mL) after retreatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of ALT normalization (ALT &lt; 40 U/L) after retreatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will calculate the rate of ALT normalization (ALT &lt; 40 U/L) after retreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBsAg change after retreatment compared with baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will investigate the rate of HBsAg change after retreatment compared with the baseline HBsAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBcrAg change after retreatment compared with baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will investigate the rate of hepatitis B core-related antigen (HBcrAg) change after retreatment compared with baseline HBcrAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of M2BPGi level change after retreatment compared with baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will investigate the rate of Mac-2 binding protein glycosylation isomer (M2BPGi) level change after retreatment compared with baseline M2BPGi level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <condition>Hepatitis B Reactivation</condition>
  <arm_group>
    <arm_group_label>Switching therapy cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical continuing therapy cohort</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemlidy</intervention_name>
    <description>25mg Tenofovir Alafenamide</description>
    <arm_group_label>Switching therapy cohort</arm_group_label>
    <other_name>Tenofovir Alafenamide (TAF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria A. Switching therapy cohort&#xD;
&#xD;
          1. Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least&#xD;
             2 years, and fulfil the following NUCs discontinuation criteria (1)HBeAg-positive&#xD;
             patients achieving HBeAg seroclearance, and received at least 1-year consolidation&#xD;
             therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1&#xD;
             year (on 3 occasions, 6 months apart)&#xD;
&#xD;
          2. After NUC discontinuation, patients had a clinical relapse (HBV DNA &gt; 2000 IU/mL, and&#xD;
             ALT &gt; 2x ULN)&#xD;
&#xD;
          3. The retreatment regimen switches to TAF (within 3 months of clinical relapse)&#xD;
&#xD;
        B. Historical continuing therapy cohort&#xD;
&#xD;
          1. Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least&#xD;
             2 years, and fulfil the following NUCs discontinuation criteria (1) HBeAg-positive&#xD;
             patients achieving HBeAg seroclearance, and received at least 1-year consolidation&#xD;
             therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1&#xD;
             year(on 3 occasions, 6 months apart)&#xD;
&#xD;
          2. After NUC discontinuation, patients had a clinical relapse (HBV DNA &gt; 2000 IU/mL, and&#xD;
             ALT &gt; 2x ULN)&#xD;
&#xD;
          3. The patients continued the original regimen (ETV, TDF) for retreatment (within 3&#xD;
             months of clinical relapse)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients who do not fulfill the discontinuation criteria&#xD;
&#xD;
          2. Patients who have HCV, HDV or HIV co-infection&#xD;
&#xD;
          3. Patients who discontinue lamivudine, adefovir, or telbivudine therapy&#xD;
&#xD;
          4. Patients with liver cirrhosis by ultrasonography and clinical diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tung-Hung Su, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tung-Hung Su, MD, PhD</last_name>
    <phone>886972651694</phone>
    <email>tunghungsu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pei-Ying Yang, MS</last_name>
    <phone>886965277228</phone>
    <email>pying0208@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital, Da-Lin Branch</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuo-Chih Tseng, MD</last_name>
      <phone>88652648000</phone>
      <phone_ext>3240</phone_ext>
      <email>tsengkuochih@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chia-Yi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Yi Chen, MD</last_name>
      <phone>88652765041</phone>
      <phone_ext>5264</phone_ext>
      <email>5137ccy@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin branch</name>
      <address>
        <city>Douliu</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Jen Fang, MD</last_name>
      <phone>886972655715</phone>
      <email>toby851072@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-da hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao-Chun Hsu, MD, PhD</last_name>
      <phone>886975209520</phone>
      <email>holdenhsu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tung-Hung Su, MD, PhD</last_name>
      <phone>886972651694</phone>
      <email>tunghungsu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu-Chi General Hospital Taipei Branch</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chia-Chi Wang, MD</last_name>
      <phone>886266289779</phone>
      <phone_ext>2317</phone_ext>
      <email>uld888@yahoo.com.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei City Hospital, Renai Branch</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Lin Lin, MD</last_name>
      <phone>886227099558</phone>
      <email>lcl@tpech.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV,clinical relapse,Vemlidy (TAF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

